% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Zuern:292493,
author = {K. Zuern and T. Hielscher$^*$ and A. Werly and I.
Breitkreutz and S. Sauer and M. S. Raab and C. Müller-Tidow
and H. Goldschmidt and E. K. Mai},
title = {{L}ongitudinal assessment of established risk
stratification models in patients with monoclonal gammopathy
of undetermined significance.},
journal = {Blood cancer journal},
volume = {14},
number = {1},
issn = {2044-5385},
address = {London [u.a.]},
publisher = {Nature Publishing Group},
reportid = {DKFZ-2024-01740},
pages = {148},
year = {2024},
abstract = {Risk of progression of monoclonal gammopathy of
undetermined significance (MGUS) into multiple myeloma and
related plasma cell disorders can be determined by three
major risk stratification models, namely Mayo2005,
Sweden2014, and NCI2019. This retrospective study of 427
patients with MGUS diagnosed according to the 2014
International Myeloma Working Group criteria aimed to
describe and analyze the longitudinal applicability of these
risk models. In all three models, the majority of patients
remained at their baseline risk group, whereas small numbers
of patients migrated to a different risk group. Proportions
of patients among risk groups remained stable over time
(e.g. Mayo2005 model, low-risk group, at baseline: $43\%,$
after 1, 2, 3, 4, 5, and 8 years: $40\%,$ $37\%,$ $37\%,$
$43\%,$ $44\%,$ and $43\%).$ All three risk models reliably
distinguished risk of progression at baseline, upon yearly
reassessment (e.g. 1 year from diagnosis) and in
time-dependent analyses. Upstaging to a high-risk category
was associated with an increased risk of progression in all
three models (Mayo2005: hazard ratio [HR] = 5.43, $95\%$
confidence interval $[95\%$ CI] 1.21-24.39, p = 0.027;
Sweden2014: HR = 13.02, $95\%$ CI 5.25-32.28, p < 0.001;
NCI2019: HR = 5.85, $95\%$ CI 2.49-13.74, p < 0.001). Our
study shows that MGUS risk stratification models can be
applied longitudinally to repeatedly determine and improve
individual risk of progression. Patient migration to higher
risk categories during follow up should prompt more frequent
monitoring in clinical routine.},
keywords = {Humans / Monoclonal Gammopathy of Undetermined
Significance: epidemiology / Monoclonal Gammopathy of
Undetermined Significance: diagnosis / Male / Female / Aged
/ Middle Aged / Disease Progression / Retrospective Studies
/ Risk Assessment / Aged, 80 and over / Longitudinal Studies
/ Adult / Multiple Myeloma: epidemiology / Multiple Myeloma:
diagnosis / Risk Factors},
cin = {C060},
ddc = {610},
cid = {I:(DE-He78)C060-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39191769},
pmc = {pmc:PMC11349746},
doi = {10.1038/s41408-024-01126-3},
url = {https://inrepo02.dkfz.de/record/292493},
}